SDS report toxicity testing provides the scientific data required to complete Section 11 (Toxicological Information) of a Safety Data Sheet and to support GHS hazard classification under global chemical regulations. Through laboratory testing following OECD test guidelines, manufacturers can determine acute toxicity, irritation, sensitization, and mutagenicity endpoints for their chemical substances and mixtures. This article explains the scope, sample requirements, testing items, standard methods, and applications of toxicity testing for SDS preparation and regulatory compliance.
Technical Overview
A Safety Data Sheet (SDS), formerly known as a Material Safety Data Sheet (MSDS), is a standardized 16-section document that communicates the hazards of chemical products along the supply chain. Under the Globally Harmonized System of Classification and Labelling of Chemicals (GHS), Section 11, titled Toxicological Information, must contain credible data on the health hazard endpoints of the substance or mixture, including acute toxicity, skin and eye effects, sensitization, mutagenicity, carcinogenicity, reproductive toxicity, specific target organ toxicity, and aspiration hazard.
SDS report toxicity testing refers to the systematic laboratory assessment of these toxicological endpoints in order to generate, verify, or supplement the data used to complete an SDS. Test results feed directly into GHS classification, which determines hazard pictograms, signal words ("Danger" or "Warning"), hazard statements (H-codes), and precautionary statements (P-codes) that appear on both the SDS and the product label. Without reliable toxicological data, an SDS may be incomplete, inaccurate, or non-compliant with frameworks such as EU CLP Regulation (EC) No 1272/2008, US OSHA HazCom 2012 (29 CFR 1910.1200), UN GHS revisions, and national implementations including GB/T 16483 and GB/T 17519 in China.
Modern toxicity testing programs follow OECD Principles of Good Laboratory Practice (GLP) and increasingly rely on validated in vitro methods and alternative approaches such as read-across, weight-of-evidence evaluation, and quantitative structure-activity relationship (QSAR) modeling to reduce animal use in accordance with the 3Rs principle (Replacement, Reduction, Refinement).
Testing Samples
Industrial Chemicals and Intermediates
Pure substances, raw materials, solvents, catalysts, monomers, and synthetic intermediates require toxicity data for registration and SDS authoring. Samples are typically submitted in tightly sealed amber glass or high-density polyethylene containers with a minimum of 10 to 100 grams or milliliters per test item, accompanied by composition information, purity, and physical-chemical data.
Mixtures and Formulated Products
Cleaning agents, coatings, adhesives, lubricants, agrochemical formulations, and polymer additives are tested either as the whole mixture or through evaluation of component data. Bridging principles under GHS may be applied when mixtures share similar compositions, reducing the volume of new testing required.
Consumer Products and Cosmetics
Household products, personal care formulations, and cosmetic ingredients often require irritation and sensitization assessment to support consumer safety documentation and regional notification requirements.
Polymers, Resins, and Specialty Materials
Low-molecular-weight polymers, reactive resins, nanomaterials, and battery chemicals may require tailored testing strategies that account for solubility, particle size, and exposure route.
Testing Items
Toxicity testing for an SDS report typically covers the following GHS health hazard endpoints:
- Acute oral toxicity (LD50 determination and Category 1 to 5 classification)
- Acute dermal toxicity
- Acute inhalation toxicity (dust, mist, vapor, or gas exposure)
- Skin corrosion and skin irritation
- Serious eye damage and eye irritation
- Skin sensitization (allergic contact dermatitis potential)
- Respiratory sensitization (where data are available)
- Germ cell mutagenicity, including bacterial reverse mutation and chromosomal effects
- Carcinogenicity evaluation, usually through literature and database review
- Reproductive and developmental toxicity, usually through literature review
- Specific target organ toxicity following single exposure (STOT-SE)
- Specific target organ toxicity following repeated exposure (STOT-RE)
- Aspiration hazard assessment based on viscosity and hydrocarbon content
- Supporting environmental endpoints such as aquatic toxicity (often reported in Section 12)
Depending on the tonnage band, intended use, and target market, the required scope may range from a basic six-endpoint screening package to a comprehensive data set supporting full chemical registration.
Testing Methods
Testing is conducted in accordance with OECD Test Guidelines, which are recognized by regulatory authorities worldwide and form the technical basis for GHS classification criteria.
Acute Toxicity Methods
- OECD TG 420: Acute Oral Toxicity, Fixed Dose Procedure
- OECD TG 423: Acute Oral Toxicity, Acute Toxic Class Method
- OECD TG 425: Acute Oral Toxicity, Up-and-Down Procedure
- OECD TG 402: Acute Dermal Toxicity
- OECD TG 403: Acute Inhalation Toxicity (and TG 436 acute toxic class for inhalation)
Skin and Eye Methods
- OECD TG 430: Transcutaneous Electrical Resistance Test (TER)
- OECD TG 431: In Vitro Skin Corrosion, Reconstructed Human Epidermis (RhE) models
- OECD TG 435: In Vitro Membrane Barrier Test for Skin Corrosion
- OECD TG 437: Bovine Corneal Opacity and Permeability (BCOP) test
- OECD TG 438 and TG 491: Isolated Chicken Eye and reconstructed human cornea models for eye irritation
- OECD TG 439: Reconstructed Human Epidermis Test for skin irritation
- OECD TG 404 and TG 405: In vivo rabbit skin and eye methods, used only when in vitro data are inconclusive
Sensitization Methods
- OECD TG 429: Local Lymph Node Assay (LLNA)
- OECD TG 442C: Direct Peptide Reactivity Assay (DPRA)
- OECD TG 442D: KeratinoSens ARE-Nrf2 luciferase test
- OECD TG 442E: U-SENS and h-CLAT cell-based assays addressing the key event of dendritic cell activation
- Defined Approaches (OECD TG 497) combining in chemico and in vitro data for hazard identification
Genotoxicity Methods
- OECD TG 471: Bacterial Reverse Mutation Test (Ames test)
- OECD TG 473: In Vitro Mammalian Chromosomal Aberration Test
- OECD TG 476: In Vitro Mammalian Cell Gene Mutation Tests
- OECD TG 487: In Vitro Mammalian Cell Micronucleus Test
- OECD TG 474 and TG 475: In vivo micronucleus and chromosomal aberration tests as follow-up
Where testing is not technically feasible or justified, data gaps can be filled using validated QSAR models, read-across from structurally analogous substances, published literature, and weight-of-evidence assessments documented in a regulatory dossier.
Applications
Toxicity testing for SDS reports supports compliance across a wide range of regulatory and commercial scenarios:
- Authoring and updating 16-section SDS documents for domestic sales and export markets
- GHS, CLP, and national hazard classification and labeling, including H-code and P-code assignment
- Chemical registration and notification programs such as EU REACH, UK REACH, K-REACH, and China new chemical substance notification (MEE Order No. 12)
- Transport of dangerous goods classification under UN Model Regulations, ADR, IMDG, and IATA DGR
- Occupational health and safety risk assessment in manufacturing and laboratory workplaces
- Customer and retailer documentation requests, including restricted substance compliance files
- Supporting data for cosmetic safety assessments and consumer product dossiers
- Due diligence for mergers, acquisitions, and product portfolio reviews
FAQ
Is animal testing always required for an SDS report?
No. Regulatory authorities strongly encourage the use of existing data, in vitro methods, read-across, and QSAR predictions before conducting new in vivo studies. Many endpoint classifications, such as skin corrosion and serious eye damage, can now be completed entirely with validated in vitro methods. Animal tests are typically considered only as a last resort when alternative approaches yield inconclusive results.
Can I use published literature or supplier data instead of testing?
Yes. Searchable sources such as the ECHA registration database, OECD eChemPortal, pubmed-indexed studies, and peer-reviewed handbooks are acceptable if the data are adequate in quality and coverage. A documented evaluation of data reliability and relevance should be retained as part of the compliance file.
How are mixtures classified when only component data are available?
For health hazards, mixtures are generally classified using ingredient concentration thresholds and additivity formulas specified in GHS and CLP. When component data are insufficient, testing of the whole mixture, bridging principles, or worst-case classification may be applied depending on the endpoint.
How long does a typical toxicity testing project take?
Individual in vitro tests such as the Ames test or skin corrosion assays generally complete within four to eight weeks. Acute toxicity studies, genotoxicity batteries, and programs requiring in vivo confirmation may extend from three to six months. A phased strategy that begins with in vitro screening often delivers the fastest route to a compliant SDS.
How often should an SDS be updated with new toxicity data?
Under most regulations, an SDS must be reviewed and updated when new hazard information becomes available, when classification changes, or at defined intervals, such as every three years under EU REACH for registered substances. Any new toxicity findings that affect classification must trigger a revision of both the SDS and the label.
What information should accompany a submitted sample?
Laboratories typically request the sample name, CAS number, composition or formulation, purity, physical state, solubility, stability information, and any known hazard data. This information enables proper test design, solvent selection, and dose-range finding.